| Literature DB >> 36226757 |
Nagwa A Shoeib1, Lamiaa A Al-Madboly2, Amany E Ragab1.
Abstract
CONTEXT: Some studies reported the chemical content and antimicrobial properties of Ocimum basilicum L. (Lamiaceae), relevant to the ecological variations in some areas of Egypt and other countries, yet no research was conducted on the plant cultivated in the central delta region of Egypt. Also, no previous data reported on inhibition of β-lactamases by O. basilicum.Entities:
Keywords: Methyl cinnamate; antimicrobial
Mesh:
Substances:
Year: 2022 PMID: 36226757 PMCID: PMC9578474 DOI: 10.1080/13880209.2022.2127791
Source DB: PubMed Journal: Pharm Biol ISSN: 1388-0209 Impact factor: 3.889
Figure 1.Analysis of essential oil and methanol extract of O. basilicum. (A) Gas chromatogram of O. basilicum essential oil with the structure of methyl cinnamate and 1,8-cineol linked to their respective peaks by arrows. UPLC-PDA-MS total ion chromatogram fingerprint of O. basilicum in (B) ESI + and (C) ESI– modes.
GC/MS of the essential oil of Ocimum basilicum L.
| No. | RT | RI | Compound | Area % |
|---|---|---|---|---|
| 1 | 9.84 | 944 | α-Pinene | 0.31 |
| 2 | 11.21 | 954 | Camphene | 0.12 |
| 3 | 11.40 | 979 | Sabinene | 0.61 |
| 4 | 11.75 | 996 | α-Myrcene | 0.18 |
| 5 | 13.43 | 1032 | 1,8-Cineol | 17.73 |
| 6 | 13.70 | 1063 | γ-Terpinene | 0.70 |
| 7 | 14.90 | 1087 | α-Terpinolene | 0.14 |
| 8 | 15.68 | 1099 | Linalool | 0.78 |
| 9 | 17.45 | 1143 | Camphor | 14.61 |
| 10 | 18.14 | 1170 | Borneol | 0.77 |
| 11 | 18.56 | 1190 | α-Terpineol | 0.12 |
| 12 | 22.04 | 1210 | Estragole | 0.71 |
| 13 | 23.66 | 1345 | α-Elemene | 0.44 |
| 14 | 24.29 | 1359 | Eugenol | 1.60 |
| 15 | 24.55–26.26 | 1373 | Methyl cinnamate | 39.99 |
| 16 | 26.84 | 1380 | α-Ylangene | 2.72 |
| 17 | 27.15 | 1512 | δ-Guaiene | 3.28 |
| 18 | 27.84 | 1409 | Methyl eugenol | 2.27 |
| 19 | 29.66 | 1631 | Cubenol | 0.13 |
| 20 | 30.42 | 1649 | α-Cadinol | 7.68 |
| Total percentage | 95.78 | |||
| Identified components | Monoterpenes | Sesquiterpenes | Non-terpene | |
| Oxygenated compounds | 35.85 | 7.81 | 43.86 | |
| Non-oxygenated compounds | 1.82 | 6.44 | ||
RT: retention time; RI: retention index was compared to the published data.
Majors are highlighted in yellow.
UPLC-PDA-MS/MS results for the methanol extract of O. basilicum L.
| No. | [M–H]– | [M + H]+ | MS2 ions | Identification | |
|---|---|---|---|---|---|
| 1 | 1.49 | 335 | 173, 131, 101 | 3- | |
| 2 | 1.72 | 335 | 245, 181, 173, 141, 131, 101 | 3- | |
| 3 | 4.11 | 197 | 197, 179, 135, 123, 109 | 3-(3,4-Dihydroxyphenyl) lactic acid | |
| 4 | 4.41 | 197 | 197, 179, 153, 135, 123, 119, 111, 96, 95 | 3-(3,4-Dihydroxyphenyl) lactic acid | |
| 5 | 6.95 | 391 | 345, 258, 215, 185, 179, 161, 138, 119, 113 | Unknown | |
| 6 | 7.01 | 391 | 345, 300, 220, 215, 193, 179, 149, 119, 113 | Unknown | |
| 7 | 7.33 | 311 | 179, 149, 135, 87 | Caftaric acid derivative | |
| 8 | 7.59 | 227 | 227, 209, 191, 173, 163, 155, 149, 137, 131, 121, 107, 105, 93, 85 | Dihydroxy caffeic acid methyl ester | |
| 9 | 7.66 | 311 | 267, 179, 168, 149, 135, 103, 87, 85 | Caftaric acid derivative | |
| 10 | 7.88 | 417 | 417, 152, 109 | Salvianolic acid D/G | |
| 11 | 7.90 | 417 | 417, 241, 219, 152, 123, 108 | Salvianolic acid D/G | |
| 12 | 7.90 | 387 | 387, 295, 219, 207, 196, 181, 163, 137, 119, 113 | Hydroxy jasmonic acid- | |
| 13 | 7.99 | 411 | 411, 380, 361, 334, 305, 263, 249, 233, 214, 203, 187, 163,155, 147, 145, 135, 129, 109 | Chlorogenic acid butyl ester | |
| 14 | 8.06 | 227 | Dihydroxy caffeic acid methyl ester isomer | ||
| 15 | 8.08 | 387 | 387, 207, 163, 119, 101, 89 | Medioresinol | |
| 16 | 8.70 | 325 | 134, 117 | Fertaric acid isomer | |
| 17 | 8.70 | 609 | 447, 285, 255, 193, 151, 125 | Kaempferol- | |
| 18 | 8.87 | 609 | 609, 301, 300, 285, 255, 193, 151, 125 | Rutin | |
| 19 | 9.15 | 537 | 339, 313, 295, 269, 229, 203, 179, 159, 135, 109 | Salvianolic acid I/H | |
| 20 | 9.35 | 537 | 295, 269, 229, 203, 197, 179, 159, 135, 109 | Salvianolic acid I/H | |
| 21 | 9.49 | 325 | 148, 134, 119, 101, 87 | Fertaric acid (feruloyl tartaric acid) | |
| 22 | 9.70 | 197 | 107, 179, 161, 143, 135, 133, 123, 119, 107, 105, 93 | Trihydroxy cinnamic acid | |
| 23 | 9.84 | 717 | 475, 431, 365, 339, 321, 309, 267, 197, 161, 109 | Rosmarinic acid dimer | |
| 24 | 9.96 | 163 | 163, 145, 135, 117, 107, 89 | Methyl cinnamate | |
| 25 | 10.36 | 197 | 197, 179, 161, 151, 143, 137, 133, 123, 119, 107, 105, 93 | Trihydroxy cinnamic acid isomer | |
| 26 | 10.43 | 163 | 163, 145, 135, 117, 107, 89 | Methyl cinnamate isomer | |
| 27 | 10.43 | 359 | 197, 179, 161, 135, 133, 123 | Rosmarinic acid isomer | |
| 28 | 10.46 | 717 | 269, 197, 179, 161, 150, 133 | Salvianolic acid B/E | |
| 29 | 10.49 | 537 | 339, 313, 295, 269, 266, 251, 203, 197, 185, 179, 135, 109 | ||
| 30 | 10.69 | 359 | 197, 179, 161, 153, 135, 133, 123, 108 | Rosmarinic acid | |
| 31 | 10.75 | 717 | 393, 357, 313, 283, 251, 225, 179, 163, 135 | Salvianolic acid B/E | |
| 32 | 10.81 | 537 | 313, 295, 251, 197, 179, 161, 135 | Lithospermic acid | |
| 33 | 11.26 | 493 | 313, 295, 277, 249, 203, 185, 159, 157, 135, 109 | Salvianolic acid A | |
| 34 | 11.54 | 535 | 197, 177, 161, 135 | Didehydrosalvianolic acid I/H | |
| 35 | 11.60 | 551 | 339, 321, 293, 277, 231, 229, 179, 135, 109 | Methyl ester of salvianolic acid H/I ester | |
| 36 | 11.95 | 535 | 284, 253, 238, 221, 197, 177, 161, 135 | Didehydrosalvianolic acid I/H | |
| 37 | 11.95 | 493 | 295, 197, 179, 159, 161, 135 | Salvianolic acid A isomer | |
| 38 | 12.17 | 551 | 339, 239, 221, 193, 161, 135 | Methyl ester of salvianolic acid H/I ester | |
| 39 | 12.48 | 327 | 327, 239, 229, 201, 185, 171, 156, 137, 127, 119, 97, 85 | Methyl ester of salvianolic acid F | |
| 40 | 13.39 | 553 | 179, 135 | Hydroxy salvianolic acid H/I | |
| 41 | 13.65 | 553 | 179, 135 | Hydroxy salvianolic acid H/I | |
| 42 | 14.39 | 849 | 359, 311, 221, 197, 161, 135 | Rosmarinic acid derivative | |
| 43 | 14.60 | 849 | 641, 507, 379, 359, 327, 309, 237, 197, 179, 161, 135 | Rosmarinic acid derivative | |
| 44 | 14.77 | 313 | 313, 237, 229, 169, 147, 133, 123, 101, 99 | Ladanein | |
| 45 | 15.07 | 313 | 297, 283, 269, 255, 229, 163 | Cirsimaritin | |
| 46 | 15.33 | 181 | 181, 163, 145, 139, 135, 125, 121, 111, 109, 107, 95, 93 | Caffeic acid | |
| 47 | 15.91 | 181 | 81, 163, 145, 140, 139, 135, 125, 124, 121, 111, 109, 107, 95, 93 | Caffeic acid isomer | |
| 48 | 18.70 | 329 | 329, 314, 296, 268, 133 | Salvigenin isomer | |
| 49 | 19.07 | 329 | 329, 314, 296, 268, 255, 237, 223, 208, 169, 135, 116, 105, 93 | Salvigenin | |
| 50 | 20.08 | 329 | 314, 299, 271, 215, 199, 182, 126 | Trihydroxy-octadecanoic acid | |
| 51 | 20.86 | 329 | 329, 293, 275, 237, 224, 209, 111, 97 | Trihydroxy-octadecadienoic acid | |
| 52 | 26.76 | 455 | 455 | Oleanolic acid | |
| 53 | 28.03 | 455 | 455 | Oleanolic acid isomer |
Rt: retention time; m/z: mass to charge ratio; [M–H]–: deprotonated pseudomolecular ion; [M + H]+: protonated pseudomolecular ion.
Resistance patterns of MDR E. coli test isolates.
| Resistance pattern | No. of isolates displaying each pattern | No. of resistant markers | MAR index |
|---|---|---|---|
| AMP-TZP-CXM-CIP-LEV-SXT | 1 | 6 | 0.35 |
| AMP-TZP-CXM-CIP-GAT-CN-AK | 3 | 7 | 0.41 |
| AMP-AMC-TZP-CXM-CTX-CIP-LEV-SXT | 2 | 8 | 0.47 |
| AMP-AMC-TZP-CXM-IMP-CIP-LEV-GAT-SXT-C | 3 | 10 | 0.59 |
| AMP-TZP-CL-CXM-CRO-CTX-FOX-CIP-CN-AK-SXT-TE-C | 1 | 13 | 0.76 |
AMP: ampicillin; AMC: amoxicillin/clavulanate; TZP: piperacillin/tazobactam; CL: cefalexin; CXM: cefuroxime; CRO: ceftriaxone; CTX: cefotaxime; FOX: cefoxitin; CIP: ciprofloxacin; LEV: levofloxacin; GAT: gatifloxacin; CN: gentamicin; AK: amikacin; SXT: trimethoprim/sulfamethoxazole; IPM: imipenem; TE: tetracycline; C: chloramphenicol.
Regarding to the different 19 antimicrobial was tested and MAR index can be calculated by dividing the number of antimicrobials to which E. coli isolate was resistant by the total number of antimicrobials to which the isolate was exposed.
Minimum inhibitory concentration of test products against E. coli isolates.
| Test isolates | MIC (µg/mL) | |||
|---|---|---|---|---|
| EO | Cineol | Camphor | Methyl cinnamate | |
| E1 | 16 | 128 | 128 | 32 |
| E2 | 8 | 64 | 128 | 64 |
| E3 | 8 | 128 | 128 | 64 |
| E4 | 8 | 64 | 128 | 64 |
| E5 | 8 | 128 | 128 | 64 |
| E6 | 8 | 64 | 128 | 32 |
| E7 | 16 | 128 | 128 | 64 |
| E8 | 8 | 64 | 128 | 64 |
| E9 | 8 | 128 | 128 | 64 |
| E10 | 16 | 64 | 128 | 64 |
| 4 | 64 | 64 | 32 | |
Figure 2.Phenotypic and genotypic screening for ESBL producing E. coli isolates using (a) double disc synergy test showing typical keyhole pattern denoting a positive ESBL producing isolate and (b) combination disc test showing increased zone diameter around the discs after addition of clavulanic acid confirming positive ESBL as referred by arrows. (c) Electrophoregram showing amplified amplicon bands at 500 bp denoting positive blaCTX-M gene.
Figure 3.Screening for β-lactamase inhibitors among test botanical agents by colorimetric method showing (a) changes in colours due to different effects against test enzyme and (b) quantitative determination of percent reduction in enzymatic activity showing methyl cinnamate and EO were able to strongly inhibit β-lactamase activity.
Figure 4.Representation of half maximal inhibitory concentration (IC50) values for both enzyme inhibitors: (a) methyl cinnamate as a test compound and (b) clavulanic acid as a standard β-lactamase inhibitor. Data presented as percent inhibition (%INH) of CTX-M against log the compound concentrations and nitrocefin as a substrate.
IC50 regression results for methyl cinnamate and clavulanic acid.
| Parameter | Value methyl cinnamate | Value clavulanic acid |
|---|---|---|
| IC50 | 11.6008 (µg/mL) | 8.1223 (µg/mL) |
| Equation | ||
| Equation form |
Figure 5.The amino acid residues involved in ligand interaction for (a) clavulanic acid and (b) methyl cinnamate.